3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
2
Active not recruiting
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
20
Sarcoma
4
Neuroendocrine Tumors
4
Neoplasms
4
Carcinoma, Medullary
4
Carcinoma, Hepatocellular
4
Urinary Bladder Neoplasms
3
Thyroid Neoplasms
3
Kidney Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Cancer, Papillary
2
Small Cell Lung Carcinoma
2
Sarcoma, Ewing
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Melanoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma
2
Adenocarcinoma, Follicular
2
Wilms Tumor
1
Urologic Neoplasms
1
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
cabozantinib
×
Clear all
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts